CAPR vs. CNTA
CAPR (Capricor Therapeutics, Inc.) and CNTA (Centessa Pharmaceuticals Limited) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CAPR returned 42.20%/yr vs 12.71%/yr for CNTA. At a 0.15 correlation, their price movements are largely independent.
Performance
CAPR vs. CNTA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CAPR achieves a -9.36% return, which is significantly lower than CNTA's 58.74% return.
CAPR
- 1D
- -2.06%
- 1M
- -13.89%
- YTD
- -9.36%
- 6M
- -8.40%
- 1Y
- 83.84%
- 3Y*
- 77.22%
- 5Y*
- 42.20%
- 10Y*
- -2.03%
CNTA
- 1D
- 0.20%
- 1M
- 0.28%
- YTD
- 58.74%
- 6M
- 34.58%
- 1Y
- 233.05%
- 3Y*
- 104.97%
- 5Y*
- 12.71%
- 10Y*
- —
CAPR vs. CNTA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CAPR Capricor Therapeutics, Inc. | -9.36% | 109.13% | 182.21% | 26.68% | 31.74% | -22.69% |
CNTA Centessa Pharmaceuticals Limited | 58.74% | 49.31% | 110.43% | 156.77% | -72.47% | -48.23% |
Correlation
The correlation between CAPR and CNTA is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2021 | 0.15 |
Fundamentals
CAPR:
-$2.32
CNTA:
-$1.81
CAPR:
$0.00
CNTA:
$15.00M
CAPR:
-$42.41M
CNTA:
$15.00M
CAPR:
-$117.24M
CNTA:
-$227.27M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CAPR vs. CNTA — Risk / Return Rank
CAPR
CNTA
CAPR vs. CNTA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Capricor Therapeutics, Inc. (CAPR) and Centessa Pharmaceuticals Limited (CNTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CAPR | CNTA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.32 | ||
| Sortino ratioReturn per unit of downside risk | -0.83 | ||
| Omega ratioGain probability vs. loss probability | 1.59 | 1.69 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 1.26 | 8.90 | -7.64 |
| Martin ratioReturn relative to average drawdown | 2.38 | 24.63 | -22.25 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CAPR | CNTA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.22 | 3.54 | -3.32 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | 0.18 | +0.05 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.01 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.08 | 0.18 | -0.26 |
Drawdowns
CAPR vs. CNTA - Drawdown Comparison
The maximum CAPR drawdown since its inception was -99.97%, which is greater than CNTA's maximum drawdown of -88.19%. Use the drawdown chart below to compare losses from any high point for CAPR and CNTA.
Loading charts...
Drawdown Indicators
| CAPR | CNTA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.97% | -88.19% | -11.78% |
Max Drawdown (1Y)Largest decline over 1 year | -67.00% | -26.38% | -40.62% |
Max Drawdown (3Y)Largest decline over 3 years | -79.08% | -43.72% | -35.36% |
Max Drawdown (5Y)Largest decline over 5 years | -79.08% | -88.19% | +9.11% |
Max Drawdown (10Y)Largest decline over 10 years | -98.02% | — | — |
Current DrawdownCurrent decline from peak | -99.20% | -0.50% | -98.70% |
Average DrawdownAverage peak-to-trough decline | -90.24% | -51.99% | -38.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.96% | 9.51% | +26.45% |
Volatility
CAPR vs. CNTA - Volatility Comparison
Capricor Therapeutics, Inc. (CAPR) has a higher volatility of 18.21% compared to Centessa Pharmaceuticals Limited (CNTA) at 0.72%. This indicates that CAPR's price experiences larger fluctuations and is considered to be riskier than CNTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CAPR | CNTA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.21% | 0.72% | +17.49% |
Volatility (6M)Calculated over the trailing 6-month period | 50.01% | 44.27% | +5.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 385.34% | 66.48% | +318.86% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 190.06% | 72.09% | +117.97% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 179.86% | 72.30% | +107.56% |
Dividends
CAPR vs. CNTA - Dividend Comparison
Neither CAPR nor CNTA has paid dividends to shareholders.
Financials
CAPR vs. CNTA - Financials Comparison
This section allows you to compare key financial metrics between Capricor Therapeutics, Inc. and Centessa Pharmaceuticals Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CAPR and CNTA have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CAPR has higher volatility (18.21%) compared to CNTA (0.72%). In terms of maximum drawdown, CAPR dropped -99.97% vs CNTA's -88.19%.
CNTA currently has the higher Sharpe Ratio (3.54 vs 0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CAPR and CNTA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer